%0 Journal Article
%T Clinical Risk Factors Associated with HIV-Tuberculosis Co-Infection Among Patients on Antiretroviral Therapy, Bungoma and Webuye County Hospitals (2015), Kenya
%J -
%D 2018
%X Tuberculosis (TB) is the leading causes of death among people living with Human Immune Deficiency Virus (HIV) and first presenting sign in majority of people living with HIV. Factors influencing TB among HIV patients on anti retroviral treatment (ART) are not well described in our settings. The study aimed to assess clinical factors influencing occurrence of TB among people living with HIV after ART initiation in Bungoma and Webuye hospitals in Bungoma County. The study population consists of 156 cases and 156 controls. Case control study conducted from January 2017- April 2017 in two public hospitals in Bungoma County. Cases were adult people living with HIV who developed TB after ART initiation and controls were adult people living with HIV who did not develop TB after ART initiation. An interviewer administered structured questionnaire was used to collect information. at 95% CI and variables with p-value of < 0.05 at multivariable logistic regression were considered as significant predictors of the outcome variable. The findings of the study were presented in text and tables. The result of this study shows that after adjusting for potential confounders not being on Isonazid (adjusted odd ratio [AOR] = 35.97, 95% confidence interval [CI] 13.81, 90.20), ), having World Health Organization (WHO) clinical stage III/IV (AOR = 15.53; 95% CI: 7.67, 31.47), having interrupted ART (AOR=2.72; 95%CI: 0.35,21.31), were predictors for increase risk of TB in PLWH after ART initiation. Not smoking (AOR=0.31;95%CI:0.13,0.71) had decreases chances of acquiring TB in PLWH after ART initiation. In this study, increasing coverage of isoniazid preventive therapy reduced risk of TB among HIV patients. Study recommends that all PLWH should be screened for TB, but for patients who have advanced disease condition (WHO clinical stage III/IV) intensified screening is highly recommended during treatment follow up
%K Antiretroviral Therapy
%K Co-Infection
%K Clinical Characteristics
%U http://www.sciencepublishinggroup.com/journal/paperinfo?journalid=651&doi=10.11648/j.ejpm.20180604.11